Aquatic Capital Management LLC Has $715,000 Stock Holdings in Alphatec Holdings, Inc. (NASDAQ:ATEC)

Aquatic Capital Management LLC lowered its position in Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 78.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 77,924 shares of the medical technology company's stock after selling 287,376 shares during the quarter. Aquatic Capital Management LLC owned 0.05% of Alphatec worth $715,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. R Squared Ltd purchased a new position in Alphatec in the fourth quarter valued at about $29,000. Nisa Investment Advisors LLC grew its position in shares of Alphatec by 973.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company's stock worth $43,000 after buying an additional 4,234 shares in the last quarter. Newton One Investments LLC bought a new stake in shares of Alphatec in the fourth quarter worth $50,000. AlphaQuest LLC bought a new stake in shares of Alphatec in the fourth quarter worth $80,000. Finally, Summit Investment Advisors Inc. raised its holdings in Alphatec by 14.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 10,890 shares of the medical technology company's stock valued at $100,000 after acquiring an additional 1,342 shares in the last quarter. 66.35% of the stock is owned by hedge funds and other institutional investors.

Alphatec Stock Performance

ATEC stock traded up $0.94 during mid-day trading on Friday, reaching $12.00. The company had a trading volume of 4,701,141 shares, compared to its average volume of 2,074,909. The stock's 50-day simple moving average is $10.46 and its two-hundred day simple moving average is $9.92. The stock has a market capitalization of $1.75 billion, a P/E ratio of -9.38 and a beta of 1.20. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21. Alphatec Holdings, Inc. has a one year low of $4.88 and a one year high of $13.79.

Alphatec (NASDAQ:ATEC - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical technology company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.23). The firm had revenue of $169.18 million during the quarter, compared to the consensus estimate of $167.57 million. Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. Alphatec's revenue for the quarter was up 22.2% on a year-over-year basis. During the same quarter last year, the company posted ($0.34) EPS. Research analysts anticipate that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Insider Activity

In other Alphatec news, EVP David Sponsel sold 36,256 shares of the firm's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $11.42, for a total transaction of $414,043.52. Following the transaction, the executive vice president now owns 735,074 shares of the company's stock, valued at approximately $8,394,545.08. This trade represents a 4.70 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Patrick Miles sold 12,691 shares of the company's stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $10.64, for a total transaction of $135,032.24. Following the completion of the sale, the chief executive officer now directly owns 5,857,603 shares of the company's stock, valued at approximately $62,324,895.92. This represents a 0.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 222,113 shares of company stock valued at $2,519,725. Company insiders own 22.80% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on ATEC shares. StockNews.com raised shares of Alphatec from a "sell" rating to a "hold" rating in a research report on Friday, February 28th. HC Wainwright restated a "buy" rating and set a $20.00 price objective on shares of Alphatec in a research note on Monday, April 14th. Barclays increased their target price on Alphatec from $20.00 to $21.00 and gave the stock an "overweight" rating in a report on Wednesday, January 22nd. Needham & Company LLC reiterated a "buy" rating and issued a $16.00 price target on shares of Alphatec in a report on Friday. Finally, Piper Sandler restated an "overweight" rating and set a $15.00 price objective (up from $13.00) on shares of Alphatec in a research note on Friday. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, Alphatec has an average rating of "Moderate Buy" and an average price target of $17.89.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.